Postmenopausal osteoporosis postmenopausal osteoporosis, zoledronate, bone mineral density, fracture, prevention
Conditions
Interventions
A single dose of 4 mg of Zoledronate given as a 15 to 30 minutes intravenous infusion in 100 mL of 0.9% NaCl. Each vial (5 mL) contains Zoledronic acid monohydrate equivalent to Zoledronic acid anhydr
Experimental Drug
zoledronate
Sponsors
Phramongkutklao hospital
Eligibility
Sex/Gender
Female
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: postmenopausal osteoporotic women from the Internal Medicine and Rheumatology Outpatient Clinic, Phramongkutklao Hospital between July 2018 and December 2019. In all the women, menopause had occurred at least five years previously, either naturally or as the result of bilateral oophorectomy. Osteoporosis is defined according to the WHO criteria, as a BMD either at the lumbar spine or hip of less than 2.5 standard deviations or more below the average value for young healthy women (a T-score of <-2.5 SD).
Exclusion criteria
Exclusion criteria: patients who previously received anti-resorptive treatment including bisphosphonate, estrogen replacement therapy, calcitonin and raloxifene, moderate to severe renal impairment (GFR < 35 mL/min estimated by CKD-EPI equation,8 allergic to bisphosphonates, planning for invasive dental surgery within 12 months after Zoledronate infusion, history of atrial fibrillation, history of hyperparathyroidism, vitamin D insufficiency and evidence of secondary osteoporosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lumbar bone mineral density 12 months Lumbar bone mineral density (g/cm2) by DXA scan | — |
Secondary
| Measure | Time frame |
|---|---|
| Total hip bone mineral density 12 months Total hip bone mineral density (g/cm2) by DXA scan | — |
Countries
Thailand
Contacts
Public ContactSumapa Chaiamnuay
Phramongkutklao hospital
Outcome results
None listed